Griffiths P D, Feinberg J E, Fry J, Sabin C, Dix L, Gor D, Ansari A, Emery V C
Virology Department, Royal Free Hospital School of Medicine, London, United Kingdom.
J Infect Dis. 1998 Jan;177(1):57-64. doi: 10.1086/513806.
Samples of blood and urine were collected at baseline, week 4, and week 8 and then every 8 weeks from 310 patients entering a controlled trial of prophylaxis with valaciclovir versus acyclovir. Samples were tested under code by polymerase chain reaction (PCR) in one laboratory. The median number of samples collected from each patient was 5 for blood (range, 0-15) and 5 for urine (range, 0-15). Both baseline PCR viremia and PCR viruria were significantly associated with future cytomegalovirus (CMV) disease (P = .002 and P = .02, respectively). The greatest effect of valaciclovir on CMV disease was seen in patients who were PCR-positive in blood at baseline (P = .002), although a significant effect was also seen in those who were PCR-negative in urine (P = .02). Thus, PCR viremia provides prognostic information about CMV disease in AIDS patients, and valaciclovir showed activity as both a preemptive and prophylactic agent.
对310名进入伐昔洛韦与阿昔洛韦预防对照试验的患者，在基线期、第4周、第8周采集血样和尿样，之后每8周采集一次。样本在一个实验室采用聚合酶链反应（PCR）进行盲法检测。每位患者采集的血样中位数为5份（范围0 - 15份），尿样中位数为5份（范围0 - 15份）。基线期PCR病毒血症和PCR病毒尿症均与未来巨细胞病毒（CMV）疾病显著相关（P值分别为0.002和0.02）。伐昔洛韦对CMV疾病的最大疗效见于基线期血样PCR呈阳性的患者（P = 0.002），不过尿样PCR呈阴性的患者也有显著疗效（P = 0.02）。因此，PCR病毒血症可为艾滋病患者的CMV疾病提供预后信息，且伐昔洛韦作为先发制人药物和预防药物均显示出活性。
